We have located links that may give you full text access.
Successful therapy with rituximab in three patients with probable neurosarcoidosis.
Background: Neurosarcoidosis occurs in about 5-15% of patients with sarcoidosis. Therapy with corticosteroids is generally accepted as the first-line medication, followed by various immunomodulating and cytotoxic agents or combined therapy. However, some patients show an unsatisfactory outcome or have adverse events and require novel treatment strategies.
Methods: We describe three patients with systemic sarcoidosis and central nervous system involvement who received CD20-targeted B-cell depletion with rituximab.
Results: Treatment with rituximab was well tolerated and followed by marked remission in patients nonresponsive to other immunosuppressive agents.
Conclusion: Rituximab may be used for patients with neurosarcoidosis who are nonresponsive to established treatment regimes.
Methods: We describe three patients with systemic sarcoidosis and central nervous system involvement who received CD20-targeted B-cell depletion with rituximab.
Results: Treatment with rituximab was well tolerated and followed by marked remission in patients nonresponsive to other immunosuppressive agents.
Conclusion: Rituximab may be used for patients with neurosarcoidosis who are nonresponsive to established treatment regimes.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app